Medical and Nonmedical Resource Utilization Associated With CIDP: Results From a Real-World International Survey
Author(s)
Febe Marloes Brackx, Ir, MSc1, Clémence Arvin-Berod, PharmD2, Sandra Paci, PhD3, Lucas Van de Veire, MA1, Yasmin Taylor, Mbiol4, Jack Wright, MSc5, Sarah Dewilde, PhD1.
1Services in Health Economics (SHE) BVBA, Schaerbeek, Belgium, 2argenx BV, Ghent, Belgium, 3argenx BV, Zwijnaarde, Belgium, 4Adelphi Real World, Bollington, United Kingdom, 5Adelphi Real World, Bollington, United Kingdom.
1Services in Health Economics (SHE) BVBA, Schaerbeek, Belgium, 2argenx BV, Ghent, Belgium, 3argenx BV, Zwijnaarde, Belgium, 4Adelphi Real World, Bollington, United Kingdom, 5Adelphi Real World, Bollington, United Kingdom.
OBJECTIVES: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that affects the peripheral nerves. This study examines medical and non-medical resource use across varying levels of patient disability.
METHODS: Data were drawn from Adelphi’s CIDP Disease Specific Programme™ (September 2022 - April 2023), a digital, multinational, real-world survey involving neurologists and their patients. In total, 542 patients from the UK, France, Germany, Italy, and Spain were included in our analysis. Disability was measured using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (range: 0-10), grouped as mild (≤2), moderate (3-4), or severe (≥5). We used the Kruskal-Wallis test for continuous variables and the Chi-squared test for categorical variables to assess associations with disability level.
RESULTS: Of the 542 patients, 236 had mild, 189 moderate, and 117 severe disability. Treatment prescription rates increased with severity (receiving treatment: mild 78.4%, moderate 89.9%, severe 92.3%; p < 0.001). Caregiver reliance rose sharply with disability (mild 7.2%, moderate 31.2%, severe 62.9%; p < 0.001), with partners/spouses being the most common caregivers.
Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p = 0.001), as were emergency admissions (11.8%, 40.5%, 46.7%; p < 0.001) and ICU stays (0.0%, 2.7%, 13.3%; p = 0.004). The use of mobility aids (18.2%, 56.1%, 89.7%) and home modifications (10.6%, 34.9%, 56.4%) also rose significantly with severity (p < 0.001 for both).
Finally, employment rates declined as disability increased (mild 65.7%, moderate 58.7%, severe 31.2%; p = 0.003).
CONCLUSIONS: CIDP is associated with a substantial and escalating burden as disability progresses. This burden extends beyond healthcare utilization, affecting caregiver support needs, hospital admissions, living conditions, and employment. These findings highlight the wide-ranging impact of CIDP and the need for comprehensive management strategies.
METHODS: Data were drawn from Adelphi’s CIDP Disease Specific Programme™ (September 2022 - April 2023), a digital, multinational, real-world survey involving neurologists and their patients. In total, 542 patients from the UK, France, Germany, Italy, and Spain were included in our analysis. Disability was measured using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (range: 0-10), grouped as mild (≤2), moderate (3-4), or severe (≥5). We used the Kruskal-Wallis test for continuous variables and the Chi-squared test for categorical variables to assess associations with disability level.
RESULTS: Of the 542 patients, 236 had mild, 189 moderate, and 117 severe disability. Treatment prescription rates increased with severity (receiving treatment: mild 78.4%, moderate 89.9%, severe 92.3%; p < 0.001). Caregiver reliance rose sharply with disability (mild 7.2%, moderate 31.2%, severe 62.9%; p < 0.001), with partners/spouses being the most common caregivers.
Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p = 0.001), as were emergency admissions (11.8%, 40.5%, 46.7%; p < 0.001) and ICU stays (0.0%, 2.7%, 13.3%; p = 0.004). The use of mobility aids (18.2%, 56.1%, 89.7%) and home modifications (10.6%, 34.9%, 56.4%) also rose significantly with severity (p < 0.001 for both).
Finally, employment rates declined as disability increased (mild 65.7%, moderate 58.7%, severe 31.2%; p = 0.003).
CONCLUSIONS: CIDP is associated with a substantial and escalating burden as disability progresses. This burden extends beyond healthcare utilization, affecting caregiver support needs, hospital admissions, living conditions, and employment. These findings highlight the wide-ranging impact of CIDP and the need for comprehensive management strategies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
SA67
Topic
Patient-Centered Research, Study Approaches
Topic Subcategory
Surveys & Expert Panels
Disease
Neurological Disorders